Search company, investor...

Progentix Orthobiology

Founded Year



Corporate Minority | Alive

Total Raised




Last Raised

$10M | 14 yrs ago

About Progentix Orthobiology

Progentix Orthobiology offers a unique osteoinductive materials for clinical application in bone regenerative surgery

Headquarters Location

Prof. Bronkhorstlaan 10-d



Missing: Progentix Orthobiology's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Progentix Orthobiology's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Progentix Orthobiology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Progentix Orthobiology is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Progentix Orthobiology Patents

Progentix Orthobiology has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Skeletal system, Human proteins, Transcription factors, Clusters of differentiation


Application Date


Grant Date



Related Topics

Skeletal system, Human proteins, Transcription factors, Clusters of differentiation



Latest Progentix Orthobiology News

Progentix Orthobiology B.V. Closes Series A Financing Round -- re> BILTHOVEN, The Netherlands, January 22 /PRNewswire/ --

Jul 19, 2013

Closes Series A Financing Round BILTHOVEN, The Netherlands, January 22 /PRNewswire/ -- Progentix Orthobiology B.V. announced today the closure of its Series A financing Round. The round was led by BioGeneration Ventures. Progentix Orthobiology B.V. was established in 2007 and develops a unique suite of osteoinductive material products for clinical application in bone regenerative surgery. Progentix bone graft material is based on surface structured ceramic biomaterial scaffolds that have the ability to attract growth factors and stems cells after implantation, which results in the induction of bone growth. These materials are not only superior to currently available synthetic ceramic bone grafts, but based on their bone healing and regeneration potential also directly compete with the gold standard of autologous bone, and the growth factors that are being used today and those under development. The Series A financing round will support further technology validation and the generation of clinical proof of principle. Dr. Joost de Bruijn, CEO of Progentix Orthobiology said: "We are extremely pleased with the support of BioGeneration Ventures. This financing round will allow us to continue building value and lay the groundwork for the launch of our first products in the near future. " "We strongly believe in the high quality of the Progentix Orthobiology technology," says Edward van Wezel M.Sc., managing partner at BioGeneration Ventures BV. "This novel technology platform will address a real medical need in the area of bone grafts. The scientific team has an excellent track record in the development of biomaterials and tissue engineering. " Dr. Clemens van Blitterswijk, professor in Tissue Regeneration at the University of Twente and former CEO of IsoTis N.V., and Edward van Wezel will join the board of directors of Progentix Orthobiology. About Biogeneration Ventures BV BioGeneration Ventures invests in Dutch Life Sciences companies. The team of BioGeneration is specialized in the evaluation of new technologies and in the management of start-up companies. BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative (NGI), NWO, the holding of the University of Leiden, and ABN-AMRO Capital. BioGeneration closely cooperates with Forbion Capital Partners ( Contact: Progentix Orthobiology B.V. Prof. Dr. Joost de Bruijn T: +31-30-2295234 E: W: BioGeneration Ventures B.V. Edward van Wezel T: +31-35-6993011 E: W: SOURCE Progentix Orthobiology

Progentix Orthobiology Frequently Asked Questions (FAQ)

  • When was Progentix Orthobiology founded?

    Progentix Orthobiology was founded in 2004.

  • What is Progentix Orthobiology's latest funding round?

    Progentix Orthobiology's latest funding round is Corporate Minority.

  • How much did Progentix Orthobiology raise?

    Progentix Orthobiology raised a total of $10M.

  • Who are the investors of Progentix Orthobiology?

    Investors of Progentix Orthobiology include NuVasive and BioGeneration Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.